SBRT for Lung Cancer: 44 Real Stories

44 stories match lung cancer and SBRT. 20 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Seven-year response journey in EGFR-mutated metastatic lung adenocarcinoma

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: pleura, brain

About 7 years after presentation with metastatic lung adenocarcinoma, he remained on targeted therapy. Gefitinib controlled the disease for 5 years; after brain progression, osimertinib followed by stereotactic radiation produced a complete intracranial response.

PubMed Central
OutcomeResponding Well
Leah, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Leah's Patient Story

Patient Info: Leah Phillips, Female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: bone (spine, pelvis); malignant right pleural…

As of July 2024, Leah remained on daily Tagrisso with stable Stage IV EGFR-mutated lung cancer, no reported progression, healing/sclerotic bone metastases, and durable response for more than 4 years.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Lung CancerLung Cancer

Second primary lung cancer treated with SBRT two years later

Patient Info: Anonymized, male, 70+

At 17 months after the second SBRT, the left-lung lesion had shrunk with no local recurrence, and the patient remained alive and walking independently.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

EGFR-mutated lung cancer with later small-cell transformation

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR L858R mutation; acquired EGFR T790M mutation

Metastatic Site: pleura/chest wall, ribs, brain, meninges,…

Disease progressed through multiple lines of therapy with brain and meningeal involvement. He died in September 2021, more than 9 years after his original 2012 diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

Stage IB squamous lung cancer: SBRT, second primary tumor, and local persistence

Patient Info: Anonymized, Female, 70+

Biomarkers: EGFR wild-type / no EGFR mutations detected

As of April 2024, the second left-lower-lobe primary remained without progression after SBRT, but the original right-lower-lobe tumor site had biopsy-confirmed persistent squamous cell carcinoma 4.3 years after SBRT and required salvage local therapy planning.

PubMed Central
OutcomeSetback / Progression
Deborah, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Deborah's Patient Story

Patient Info: Deborah Persinger, Female, 70+ | Stage IV

Metastatic Site: Brain

As of January 2024, Deborah was living actively 13 years after lung cancer diagnosis, with recurrent brain metastases managed through repeated Gamma Knife radiosurgery and ongoing MRI surveillance.

Cleveland Clinic
OutcomeLiving With Cancer
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Severe colitis from pembrolizumab immunotherapy requiring additional treatment

Patient Info: Anonymized, Male

Infliximab stopped the bleeding and reduced bowel movements from 11–12 to about 3–4 per day within 1 week, allowing discharge. Continued follow-up was needed for the colitis, hepatitis B reactivation risk and lung cancer.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

BRCA2-Mutated Metastatic Lung Adenocarcinoma Controlled for 30 Months With Olaparib

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: PD-L1-negative; BRCA2 mutation; ATM mutation; EGFR-negative; ALK-negative

Metastatic Site: brain

Olaparib provided about 30 months of disease control, and PET imaging remained overall stable when a separate new breast primary was found in February 2023.

PubMed Central
OutcomeStable Disease
Terri, who was diagnosed with Stage I Lung CancerLung Cancer

Stage I Lung Cancer: Terri's Survivor Story

Patient Info: Terri Ann DiJulio, Female, 40s | Stage I

Biomarkers: Not reported for patient; family history of lung cancer noted

As of June 2023, Terri Ann was considered no evidence of disease after 3 early-stage lung cancer diagnoses treated with surgery and SBRT, and she had returned to 6-month follow-up while continuing advocacy and cycling.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

Immunotherapy and surgery for lung adenocarcinoma with two brain metastases

Patient Info: Anonymized, Female, 50s

Biomarkers: PD-L1 100%; no actionable mutations on next-generation sequencing.

After brain surgery, radiation, 11 cycles of pembrolizumab, and lung surgery, she was off treatment and under observation in remission.

PubMed Central
OutcomeCancer-Free / NED
Terri, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage III KRAS Non-Small Cell Lung Cancer: Terri's Survivor Story

Patient Info: Terri Conneran, Female | Stage III

Biomarkers: KRAS-mutated; PD-L1 level reviewed/tested

As of March 2021, Terri had Stage IIIA KRAS-mutated NSCLC with 3 local recurrences treated over time and had again reached no evidence of disease while continuing close surveillance and advocacy through KRAS Kickers.

The Patient Story
OutcomeCancer-Free / NED
Deborah, who was diagnosed with Stage I Lung CancerLung Cancer

Stage I Lung Cancer: Deborah's Patient Story

Patient Info: Deborah Schroeder, Female | Stage I

As of December 2020, Deborah had completed 3 separate 4-day SBRT courses for Stage I lung cancers and remained under monitoring for about 10 tiny lung nodules that had been stable for years.

MD Anderson
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Durable brain and leptomeningeal response to pembrolizumab in Stage IV lung cancer

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: PD-L1 high positive; EGFR negative; BRAF negative; KRAS negative; ROS1 negative; ALK negative

Metastatic Site: right adrenal gland, left sixth rib, brain,…

After 29 pembrolizumab cycles over 20 months, imaging showed no leptomeningeal disease, resolution of 3 brain lesions and marked reduction of the dominant frontal lesion; she remained neurologically intact and radiographically stable.

PubMed Central
OutcomeResponding Well
Cynthia, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Cynthia's Patient Story

Patient Info: Cynthia Hess, Female | Stage IV

Metastatic Site: Spine

As of October 2018, Cynthia’s spine metastasis had stopped growing after one stereotactic spinal radiosurgery treatment, her neck pain had subsided and future MRI scans were planned for monitoring.

Cleveland Clinic
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV ERBB2-Mutated Lung Adenocarcinoma With Brain Metastases and Multiple Targeted Therapies

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: ERBB2 exon 20 insertion, exact sequence not specified. ERBB2 copy-number gain was identified during progression on afatinib.

Metastatic Site: brain, adrenal gland, liver

The final documented afatinib plus bevacizumab rechallenge produced a mixed response followed by liver progression after 3 months.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage I Lung CancerLung Cancer

Stage IA lung cancer: no local recurrence 40 months after SBRT

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: Serum CEA elevated before SBRT; KL-6 normal; SP-D normal. Tumor genomic biomarkers not reported.

Alive without local recurrence 40 months after SBRT, after suspicious post-radiation consolidation was monitored and biopsy showed no cancer cells.

PubMed Central
OutcomeCancer-Free / NED